Literature DB >> 19796859

Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes.

Sienna R Craig1, Lisa V Adams, Stephen P Spielberg, Benjamin Campbell.   

Abstract

The lack of affordable, available pediatric drug formulations presents serious global health challenges. This article argues that successful pharmacotherapy for children demands an interdisciplinary approach. There is a need to develop new medicines to address acute and chronic illnesses of children, but also to produce formulations of essential medicines to optimize stability, bioavailability, palatability, cost, accurate dosing and adherence. This, in turn, requires an understanding of the social ecologies in which treatment occurs. Understanding health worker, caregiver and patient practices, limitations, and expectations with regard to medicines is crucial to guiding effective drug development and administration. Using literature on pediatric tuberculosis as a reference, this review highlights sociocultural, pharmacological, and structural barriers that impede the delivery of medicines to children. It serves as a basis for the development of an intensive survey of patient, caregiver, and health care worker understandings of, and preferences for, pediatric formulations in three East African countries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796859     DOI: 10.1016/j.socscimed.2009.08.024

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  9 in total

1.  Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals.

Authors:  Benjamin R Phelps; Sarah J Hathcock; Jennifer Werdenberg; Gordon E Schutze
Journal:  J Int AIDS Soc       Date:  2010-12-06       Impact factor: 5.396

2.  The "child size medicines" concept: policy provisions in Uganda.

Authors:  Jasper Ogwal-Okeng; Anthony Mbonye; Freddie Ssengooba; Rebecca Nantanda; Herbert Muyinda; Ebba Holme Hansen; Xavier Nsabagasani
Journal:  J Pharm Policy Pract       Date:  2015-01-31

3.  The financial impact of the 'zero-markup policy for essential drugs' on patients in county hospitals in western rural China.

Authors:  Zhongliang Zhou; Yanfang Su; Benjamin Campbell; Zhiying Zhou; Jianmin Gao; Qiang Yu; Jiuhao Chen; Yishan Pan
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

4.  Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.

Authors:  D T Wademan; L Busakwe; T J Nicholson; M van der Zalm; M Palmer; J Workman; A Turkova; A M Crook; M J Thomason; D M Gibb; J Seeley; A Hesseling; G Hoddinott
Journal:  Int J Tuberc Lung Dis       Date:  2019-12-01       Impact factor: 2.373

Review 5.  Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?

Authors:  Lehlogonolo N F Maphalle; Bozena B Michniak-Kohn; Modupe O Ogunrombi; Oluwatoyin A Adeleke
Journal:  Children (Basel)       Date:  2022-07-27

Review 6.  Safety of integrated preventive chemotherapy for neglected tropical diseases.

Authors:  Allan M Ciciriello; Jessica K Fairley; Emma Cooke; Paul M Emerson; Pamela J Hooper; Birgit Bolton; Genevieve LaCon; David G Addiss
Journal:  PLoS Negl Trop Dis       Date:  2022-09-29

7.  The Novelty of Inhalable Medications: Interest, Use, and Impact of Inhalant Medications in Low-Resource Settings.

Authors:  Emily R MacGuire; Katelin Moran; Bonnie J Hepler; Doris J Rouse
Journal:  East Afr Health Res J       Date:  2018-04-01

8.  Children's medicines in Tanzania: a national survey of administration practices and preferences.

Authors:  Lisa V Adams; Sienna R Craig; Elia John Mmbaga; Helga Naburi; Timothy Lahey; Cameron T Nutt; Rodrick Kisenge; Gary J Noel; Stephen P Spielberg
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

9.  Optimal Design, Characterization and Preliminary Safety Evaluation of an Edible Orodispersible Formulation for Pediatric Tuberculosis Pharmacotherapy.

Authors:  Nyaradzo Matawo; Oluwatoyin A Adeleke; James Wesley-Smith
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.